Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/30/2026 12:42 PDT] Aprea Therapeutics, Inc. (NASDAQ:APRE), Up By 100% ($0.68) From $0.683 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/30/2026 07:07 PDT] APRE Expected to Trade Up After Bullish Patterns Develop
• [03/25/2026 07:23 PDT] APRE Expected to Trade Down After Bearish Patterns Develop
• [03/12/2026 10:30 PDT] Aprea Therapeutics, Inc. (NASDAQ:APRE), Down By 100% ($0.89) From $0.89 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/03/2026 07:16 PST] APRE Expected to Trade Down After Bearish Patterns Develop
• [02/20/2026 07:15 PST] APRE Expected to Trade Up After Bullish Patterns Develop